Colorectal patients with poor response to bevacizumab had increased Ang2 serum levels, and VEGF and Ang2 blockade delayed tumor growth, normalized tumor vasculature, and increased survival (50, 51). The gene discussed is ANGPT2; the disease is neoplasm.